TROMSO, Norway, November 20 /PRNewswire/ -- The Scandinavian-based drug development company Lytix Biopharma has announced results of studies on its lead antimicrobial candidate LTX-109. Presented at ICAAC in Washington, DC, the studies showed that the novel lytic peptidomimetic has an ultra-rapid bacteriocidal effect, significantly better towards killing Staphylococcus aureus and Streptococcus pyogenes than marketed gold standard drugs. In addition to this it has proven effective against a wide range of 110 European Pseudomonas aeruginosa clinical isolates, a problrmatic Gram (-) bacterium.
According to Lytix Biopharma spokesperson Anders Fugelli, these are important studies: "The fact that LTX-109 is effective against a broad range of pathogens highlights its potential utility as a truly novel broad spectrum antimicrobial drug. Indeed it is so effective, that although the initial formulation is for the treatment of skin infections, we could now consider it for other indications such as skin and nail fungal infections, acne and oropharyngeal candidaisis. We are now in the final stages of preclinical development and look forward to taking LtX-109 into the clinic in during the second half of 2009."
LTX-109 is a novel synthetic antimicrobial pepitidomimetic (SAMP) drug with a rapid bactericidal mode of action that can effectively synthesized in scalable, low-cost chemical reactor systems.
About Lytix Biopharma AS
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments. Lytix was established in 2003 to commercialise world-class research in the field of lytic peptides spun out by the founding scientists working in the University Hospital and University of Tromso in Norway.
Operating out of a main office located in Tromso and through our continued collaboration with the University of Tromso the Company has access to state-of-the-art laboratories and staff with extensive experience of developing peptide based drugs, including preparation of peptidomimetics. Business and product development is driven from the subsidiary office in Oslo.
CONTACT: Corporate Inquiries, Anders Fugelli, Head of Business
Development, Lytix Biopharma AS, P.O. Box 6447, Tromso Research Park,
N-9294 Tromso, Norway, Tel +47-924-81-432, Email:
anders.fugelli@lytixbiopharma.com; Media Inquiries, Richard Hayhurst,
Hayhurst Media, Tel +44(0)7711821527, Email: Richard@hayhurstmedia.com
